Barinthus Biotherapeutics Plc. Operating Income

Barinthus Biotherapeutics Plc. (BRNS) currently reports a operating income of $-17M as of June 2026. That compares with $-45M in the prior-year period — up 62.6% year over year. Use the charts on this page to explore Barinthus Biotherapeutics Plc.'s operating income history and peer comparisons.

Barinthus Biotherapeutics Plc.'s operating income increased from $-45M to $-17M — a 62.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Barinthus Biotherapeutics Plc. reported $-17M in operating income as of June 2026. That compares with $-45M in the prior-year period — up 62.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-17M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Barinthus Biotherapeutics Plc., and consider following BRNS for alerts when major investors trade the stock.

Barinthus Biotherapeutics Plc. is classified in the Healthcare sector. On operating income, it currently shows $-17M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BRNS with unrelated industries.